Evidence map›Paper›PMID 34517248›Full record

ArticleJournal of affective disorders2021

Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review.

Michele Fornaro, Michele De Prisco, Martina Billeci, Eleonora Ermini, Allan H Young, Beny Lafer, Jair C Soares, Eduard Vieta, Joao Quevedo, Andrea de Bartolomeis and 7 more

Open access · greenAbstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of affective disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 5 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 5 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Effect of psychotropics on the risk of COVID-19 in middle-aged and older adults.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2023
    Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 10 countries.

Michele FornaroSection on Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology Federico II University of Naples, Naples, Italy.
Michele De PriscoSection on Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology Federico II University of Naples, Naples, Italy.
Martina BilleciSection on Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology Federico II University of Naples, Naples, Italy.
Eleonora ErminiSection on Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology Federico II University of Naples, Naples, Italy.
Allan H YoungDepartment of Psychological Medicine, Psychology and Neuroscience, Institute of Psychiatry, King's College London & South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Beckenham, Kent BR3 3BX, UK.
Beny LaferBipolar Research Program, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.
Jair C SoaresDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, USA.
Eduard VietaInstitute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia 08036, Spain.
Joao QuevedoTranslational Psychiatry Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, SC, Brazil; Department of Psychiatry and Behavioral Sciences, Translational Psychiatry Program, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Center of Excellence On Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA; Neuroscience Graduate Program, University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Andrea de BartolomeisSection on Psychiatry, Department of Neuroscience, Reproductive Science and Odontostomatology Federico II University of Naples, Naples, Italy; Laboratory of Molecular and Translational Psychiatry and Unit of Treatment-Resistant Psychosis, University of Naples Federico II, Italy; Staff of Unesco Chair for Health Education and Sustainable Development, Naples, Italy.
Kang SimInstitute of Mental Health Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Lakshmi N YathamDepartment of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Michael BauerDepartment of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus Medical Faculty, Technische Universität Dresden, Dresden, Germany.
Dan J SteinDepartment of Psychiatry and Neuroscience Institute, SAMRC Unit on Risk & Resilience in Mental Disorders, University of Cape Town, Cape Town, South Africa.
Marco SolmiDepartment of Psychiatry, University of Ottawa, Ottawa, ON, Canada; Department of Mental Health, The Ottawa Hospital, Ottawa, ON, Canada.
Michael BerkIMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia; Department of Psychiatry, Orygen, The National Centre of Excellence in Youth Mental Health, The University of Melbourne, Parkville, Australia; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.
Andre F CarvalhoIMPACT, The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia. Electronic address: andrefc7@hotmail.com.
University of Naples Federico II · ITBarwon Health · AUCentro de Investigación Biomédica en Red de Salud Mental · ESFederico II University Hospital · ITKing's College London · GBNational University of Singapore · SGSouth African Medical Research Council · ZAThe University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · USUniversidade de São Paulo · BRUniversity Hospital Carl Gustav Carus · DEUniversity of British Columbia · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe COVID-19 (coronavirus disease 2019)-related pandemic represents a global source of societal and health burden. Yet, the impact of the pandemic on people with severe mental illness, including bipolar disorder (BD), remains unclear, warranting scoping review on the matter.

methodsThe MEDLINE and EMBASE databases were systematically searched from inception up to April 24, 2021, adopting broad inclusion criteria to assess a variety of clinical and public health themes related to people with a primary diagnosis of BD during the COVID-19 pandemics. The present work complying with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) registered in the Open Science Framework (OSF) repository (https://osf.io/7evpx/).

resultsFourteen papers informed the present scoping review. Four major themes were identified: (i) impact of COVID-19-related stressors on BD; (ii) impact of COVID-19 on mental health service utilization among people with BD; (iii) impact of BD on the risk of acquiring SARS-CoV-2 infection; (iv) engagement in preventative behaviors among people with BD. Additional themes warranting further research were nonetheless detected. LIMITATIONS: Further original studies are needed.

conclusionThe present study confirmed the high-vulnerability hypothesis concerning people with BD versus the general population, reinforcing the need for further research related to the COVID-19 pandemic. Additional information is warranted to compare the impact of the pandemic period among BD people against pre-pandemic records, the general population, and other severe mental illnesses, namely people with schizophrenia or major depressive disorder, to inform the public health and the delivery of patient-tailored interventions.

Indexed as

Bipolar DisorderCOVID-19Major Depressive DisorderHumansPandemicsSARS-CoV-2

Identifiers

PMID34517248
PMCPMC8416293
OpenAlexW3197478567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.